Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Nov 6;515(7525):134-7.
doi: 10.1038/nature13638. Epub 2014 Aug 24.

Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer

Affiliations

Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer

Diletta Di Mitri et al. Nature. .

Abstract

Aberrant activation of oncogenes or loss of tumour suppressor genes opposes malignant transformation by triggering a stable arrest in cell growth, which is termed cellular senescence. This process is finely tuned by both cell-autonomous and non-cell-autonomous mechanisms that regulate the entry of tumour cells to senescence. Whether tumour-infiltrating immune cells can oppose senescence is unknown. Here we show that at the onset of senescence, PTEN null prostate tumours in mice are massively infiltrated by a population of CD11b(+)Gr-1(+) myeloid cells that protect a fraction of proliferating tumour cells from senescence, thus sustaining tumour growth. Mechanistically, we found that Gr-1(+) cells antagonize senescence in a paracrine manner by interfering with the senescence-associated secretory phenotype of the tumour through the secretion of interleukin-1 receptor antagonist (IL-1RA). Strikingly, Pten-loss-induced cellular senescence was enhanced in vivo when Il1ra knockout myeloid cells were adoptively transferred to PTEN null mice. Therapeutically, docetaxel-induced senescence and efficacy were higher in PTEN null tumours when the percentage of tumour-infiltrating CD11b(+)Gr-1(+) myeloid cells was reduced using an antagonist of CXC chemokine receptor 2 (CXCR2). Taken together, our findings identify a novel non-cell-autonomous network, established by innate immunity, that controls senescence evasion and chemoresistance. Targeting this network provides novel opportunities for cancer therapy.

PubMed Disclaimer

Comment in

Similar articles

Cited by

References

    1. Nat Protoc. 2010 Apr;5(4):702-13 - PubMed
    1. Cancer Cell. 2008 Mar;13(3):193-205 - PubMed
    1. Nature. 2004 Mar 25;428(6981):431-7 - PubMed
    1. PLoS Biol. 2003 Dec;1(3):E59 - PubMed
    1. FASEB J. 2010 May;24(5):1365-75 - PubMed

Publication types

MeSH terms

Associated data